Cytochrome P450-mediated drug metabolism in the brain.

Cytochrome P450 enzymes (CYPs) metabolize many drugs that act on the central nervous system (CNS), such as antidepressants and antipsychotics; drugs of abuse; endogenous neurochemicals, such as serotonin and dopamine; neurotoxins; and carcinogens. This takes place primarily in the liver, but metabolism can also occur in extrahepatic organs, including the brain. This is important for CNS-acting drugs, as variation in brain CYP-mediated metabolism may be a contributing factor when plasma levels do not predict drug response. This review summarizes the characterization of CYPs in the brain, using examples from the CYP2 subfamily, and discusses sources of variation in brain CYP levels and metabolism. Some recent experiments are described that demonstrate how changes in brain CYP metabolism can influence drug response, toxicity and drug-induced behaviours. Advancing knowledge of brain CYP-mediated metabolism may help us understand why patients respond differently to drugs used in psychiatry and predict risk for psychiatric disorders, including neurodegenerative diseases and substance abuse.

[1]  R. Michels,et al.  Progress in Psychiatry , 1904, The Hospital.

[2]  H. Woods,et al.  5-Hydroxytryptamine synthesis in the isolated perfused rat brain. , 1975, British journal of pharmacology.

[3]  J. Fishman,et al.  N-demethylation of morphine in rat brain is localised in sites with high opiate receptor content , 1976, Nature.

[4]  H. Woods,et al.  Some histological and metabolic properties of an isolated perfused rat brain preparation with special reference to monoamine metabolism , 1976, Neuroscience.

[5]  M. Ames,et al.  Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites. , 1977, Biochemical and biophysical research communications.

[6]  S. Paul,et al.  Catechol estrogen-forming enzyme of brain: demonstration of a cytochrome p450 monooxygenase. , 1977, Endocrinology.

[7]  G. Siest,et al.  Subcellular distribution of cytochrome P-450 in the brain , 1986, Brain Research.

[8]  J. Gustafsson,et al.  Regional Distribution of Cytochrome P‐450 in the Rat Brain: Spectral Quantitation and Contribution of P‐450b,e and P‐450c,d , 1988, Journal of neurochemistry.

[9]  J. Chambers,et al.  Activation and degradation of the phosphorothionate insecticides parathion and EPN by rat brain. , 1989, Biochemical pharmacology.

[10]  S. Shankar,et al.  Xenobiotic metabolism in human brain — presence of cytochrome P-450 and associated mono-oxygenases , 1989, Brain Research.

[11]  C. Alm,et al.  DEBRISOQUINE HYDROXYLATION POLYMORPHISM AND PERSONALITY , 1989, The Lancet.

[12]  S. Shankar,et al.  Rat brain cytochromes P-450: catalytic, immunochemical properties and inducibility of multiple forms , 1990, Brain Research.

[13]  J. Gustafsson,et al.  Cytochrome P-450 in the brain. , 1990, Biochemical Society transactions.

[14]  G. Siest,et al.  Distribution of cytochrome P450 activities towards alkoxyresorufin derivatives in rat brain regions, subcellular fractions and isolated cerebral microvessels. , 1990, Biochemical pharmacology.

[15]  F. Oesch,et al.  Mapping of phenytoin-inducible cytochrome P450 immunoreactivity in the mouse central nervous system , 1991, Neuroscience.

[16]  G. Siest,et al.  Drug metabolizing enzymes in the brain and cerebral microvessels , 1991, Brain Research Reviews.

[17]  T. Cresteil,et al.  Expression of CYP2D6 in developing human liver. , 1991, European journal of biochemistry.

[18]  R. Melcangi,et al.  Testosterone metabolism in brain cells and membranes , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[19]  V. Ravindranath,et al.  Protection and potentiation of MPTP-induced toxicity by cytochrome P-450 inhibitors and inducer: in vitro studies with brain slices , 1991, Brain Research.

[20]  J. Lake,et al.  Rodent model of nicotine abstinence syndrome , 1992, Pharmacology Biochemistry and Behavior.

[21]  C. J. Omiecinski,et al.  Regiospecific expression of cytochrome P-450s and microsomal epoxide hydrolase in human brain tissue. , 1993, Journal of toxicology and environmental health.

[22]  M. Komori.  A novel P450 expressed at the high level in rat brain. , 1993, Biochemical and biophysical research communications.

[23]  P. Bushnell,et al.  Behavioral and neurochemical effects of acute chlorpyrifos in rats: tolerance to prolonged inhibition of cholinesterase. , 1993, The Journal of pharmacology and experimental therapeutics.

[24]  L. Bertilsson,et al.  Relationship between personality and debrisoquine hydroxylation capacity , 1993, Acta psychiatrica Scandinavica.

[25]  M. Boyd,et al.  Purification of multiple forms of cytochrome P450 from a human brain and reconstitution of catalytic activities. , 1993, Archives of Biochemistry and Biophysics.

[26]  J. Leysen,et al.  Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. , 1994, The Journal of clinical psychiatry.

[27]  L G Sultatos,et al.  Mammalian toxicology of organophosphorus pesticides. , 1994, Journal of toxicology and environmental health.

[28]  G. Siest,et al.  Dextromethorphan O-demethylase activity in rat brain microsomes , 1995, Neuroscience Letters.

[29]  H. Strobel,et al.  cDNA cloning of a novel rat brain cytochrome P450 belonging to the CYP2D subfamily. , 1995, Biochemical and biophysical research communications.

[30]  Tung-Hu Tsai,et al.  Concentration and regional distribution of propofol in brain and spinal cord during propofol anesthesia in the rat , 1995, Neuroscience Letters.

[31]  B. Lacarelle,et al.  Glucuronidation of Propofol in Microsomal Fractions from Various Tissues and Species Including Humans: Effect of Different Drugs , 1995, Anesthesia and analgesia.

[32]  C. Mazure,et al.  Desipramine treatment of major depression in patients over 75 years of age. , 1995, Journal of clinical psychopharmacology.

[33]  V. Ravindranath,et al.  Protection and Potentiation of 1‐Methyl‐4‐Phenylpyridinium‐Induced Toxicity by Cytochrome P450 Inhibitors and Inducer May Be Due to the Altered Uptake of the Toxin , 1995, Journal of neurochemistry.

[34]  P. Emson,et al.  Regional distribution of cytochrome P450 2D1 in the rat central nervous system , 1996, The Journal of comparative neurology.

[35]  H. Strobel,et al.  cDNA cloning of a novel CYP3A from rat brain. , 1996, Biochemical and biophysical research communications.

[36]  D. Nelson,et al.  Genomic Cloning and Protein Expression of a Novel Rat Brain Cytochrome P-450 CYP2D18* Catalyzing Imipramine N-Demethylation* , 1996, The Journal of Biological Chemistry.

[37]  J. Gustafsson,et al.  Cytochrome P4502D4 in the brain: specific neuronal regulation by clozapine and toluene. , 1996, Molecular pharmacology.

[38]  H. Strobel,et al.  Cytochrome P450-dependent biotransformation of drugs and other xenobiotic substrates in neural tissue. , 1997, Drug metabolism reviews.

[39]  C. J. Gordon,et al.  Hypothermia and delayed fever in the male and female rat exposed to chlorpyrifos. , 1997, Toxicology.

[40]  D. L. Le Couteur,et al.  The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis , 1997, Journal of the Neurological Sciences.

[41]  S. Imaoka,et al.  Dopamine formation from tyramine by CYP2D6. , 1998, Biochemical and biophysical research communications.

[42]  T. Chang,et al.  Effect of androgen administration during puberty on hepatic CYP2C11, CYP3A, and CYP2A1 expression in adult female rats. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[43]  W. Trager,et al.  Mechanism-based inactivation of cytochrome P450 2B1 by 8-methoxypsoralen and several other furanocoumarins. , 1998, Biochemistry.

[44]  Volk,et al.  Testosterone Metabolism In Rat Brain Is Differentially Enhanced By Phenytoin‐Inducible Cytochrome P450 Isoforms , 1999, Journal of neuroendocrinology.

[45]  R. Tyndale,et al.  Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[46]  S. Yamamoto,et al.  Biphasic kinetics of imipramine N-oxidation in rat brain microsomes. , 1999, Biological & pharmaceutical bulletin.

[47]  C. J. Omiecinski,et al.  Activation of cytochrome P450 gene expression in the rat brain by phenobarbital-like inducers. , 2000, The Journal of pharmacology and experimental therapeutics.

[48]  G. Tucker,et al.  The 1'-hydroxylation of Rac-bufuralol by rat brain microsomes. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[49]  E. Krieg,et al.  Neurologic function among termiticide applicators exposed to chlorpyrifos. , 2000, Environmental health perspectives.

[50]  M. Boyd,et al.  Cytochrome P4502E (CYP2E) in brain: constitutive expression, induction by ethanol and localization by fluorescence in situ hybridization. , 2000, Archives of biochemistry and biophysics.

[51]  L. Lubbers,et al.  Distribution of mRNAs encoding the arylhydrocarbon receptor, arylhydrocarbon receptor nuclear translocator, and arylhydrocarbon receptor nuclear translocator‐2 in the rat brain and brainstem , 2000, The Journal of comparative neurology.

[52]  W. Chimbira,et al.  The effect of smoking on postoperative nausea and vomiting , 1998, Anaesthesia.

[53]  N. Avadhani,et al.  Accumulation of Mitochondrial P450MT2, NH2-terminal Truncated Cytochrome P4501A1 in Rat Brain during Chronic Treatment with β-Naphthoflavone , 2000, The Journal of Biological Chemistry.

[54]  R. Tyndale,et al.  Regional and cellular distribution of CYP2D subfamily members in rat brain , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[55]  D. Ballou,et al.  Mechanistic studies of cytochrome P450 2B1 inactivation by xanthates. , 2000, Archives of biochemistry and biophysics.

[56]  R. Tyndale,et al.  Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. , 2000, Biochemical pharmacology.

[57]  M. Negishi,et al.  Regulation of cytochrome P450 (CYP) genes by nuclear receptors. , 2000, The Biochemical journal.

[58]  J. Goldstein,et al.  Metabolism of chlorpyrifos by human cytochrome P450 isoforms and human, mouse, and rat liver microsomes. , 2001, Drug metabolism and disposition: the biological fate of chemicals.

[59]  D. Black,et al.  Alternative RNA splicing in the nervous system , 2001, Progress in Neurobiology.

[60]  R. Tyndale,et al.  Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. , 2001, Biochemical pharmacology.

[61]  M. Cebrián,et al.  Cytochrome P450 2B (CYP2B)-mediated activation of methyl-parathion in rat brain extracts. , 2001, Toxicology letters.

[62]  B. Volk,et al.  Expression and localization of the CYP2B subfamily predominantly in neurones of rat brain , 2001, Journal of neurochemistry.

[63]  S. Imaoka,et al.  Progesterone oxidation by cytochrome P450 2D isoforms in the brain. , 2001, Endocrinology.

[64]  Sharon Miksys,et al.  Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics , 2002, Journal of neurochemistry.

[65]  M. Roberts,et al.  Distribution kinetics of solutes in the isolated in‐situ perfused rat head using the multiple indicator dilution technique and a physiological two‐barrier model , 2002, The Journal of pharmacy and pharmacology.

[66]  R. Boulieu,et al.  Propofol metabolites in man following propofol induction and maintenance. , 2002, British journal of anaesthesia.

[67]  U. Meyer,et al.  Cytochrome P450 CYP1A1 accumulates in the cytosol of kidney and brain and is activated by heme. , 2002, Molecular pharmacology.

[68]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.

[69]  Ai-Ming Yu,et al.  Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. , 2003, Pharmacogenetics.

[70]  E. Masliah,et al.  Overexpression of CYP2D6 attenuates the toxicity of MPP+ in actively dividing and differentiated PC12 cells. , 2003, Gene Expression.

[71]  D. Mash,et al.  Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain , 2003, Neuropharmacology.

[72]  B. Volk,et al.  Predominantly neuronal expression of cytochrome P450 isoforms cyp3a11 and cyp3a13 in mouse brain , 2003, Neuroscience.

[73]  K. Miczek,et al.  Neurosteroids, GABAA receptors, and escalated aggressive behavior , 2003, Hormones and Behavior.

[74]  R. Evans,et al.  A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. , 2003, Current drug metabolism.

[75]  Sharon Miksys,et al.  Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics , 2003, British journal of pharmacology.

[76]  J. Morrison,et al.  Adult male rat hippocampus synthesizes estradiol from pregnenolone by cytochromes P45017alpha and P450 aromatase localized in neurons. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[77]  P. Joyce,et al.  Association between cytochrome P450 2D6 genotype and harm avoidance , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[78]  Magnus Ingelman-Sundberg,et al.  Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[79]  Christophe Tzourio,et al.  CYP2D6 polymorphism, pesticide exposure, and Parkinson's disease , 2004, Annals of neurology.

[80]  T. Yokoi,et al.  Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. , 2004, Drug metabolism and pharmacokinetics.

[81]  Mitsuru Hashida,et al.  Assessment of Drug Disposition in the Perfused Rat Brain by Statistical Moment Analysis , 1991, Pharmaceutical Research.

[82]  S. Lie,et al.  Cigarette smoking in Parkinson's disease: Influence on disease progression , 2004, Movement disorders : official journal of the Movement Disorder Society.

[83]  R. Tyndale,et al.  The Unique Regulation of Brain Cytochrome P450 2 (CYP2) Family Enzymes by Drugs and Genetics , 2004, Drug metabolism reviews.

[84]  J. Idle,et al.  Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates , 2004, Drug metabolism reviews.

[85]  S. Strom,et al.  PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. , 2004, Toxicology and applied pharmacology.

[86]  K. Carroll,et al.  The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. , 2004, Toxicology and applied pharmacology.

[87]  Yifu Deng,et al.  Further evidence that interactions between CYP2D6 and pesticide exposure increase risk for Parkinson's disease , 2004, Annals of neurology.

[88]  S. Moreno,et al.  Immunolocalization of peroxisome proliferator-activated receptors and retinoid x receptors in the adult rat CNS , 2004, Neuroscience.

[89]  S. Strom,et al.  Expression of Constitutive Androstane Receptor Splice Variants in Human Tissues and Their Functional Consequences , 2004, Journal of Pharmacology and Experimental Therapeutics.

[90]  M. Roberts,et al.  An Isolated In-Situ Rat Head Perfusion Model for Pharmacokinetic Studies , 2000, Pharmaceutical Research.

[91]  W. Corrigall,et al.  Nicotine maintains robust self-administration in rats on a limited-access schedule , 2004, Psychopharmacology.

[92]  D. Greenblatt,et al.  Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. , 2004, Pharmacogenetics.

[93]  P. du Souich,et al.  5‐Hydroxytryptamine is biotransformed by CYP2C9, 2C19 and 2B6 to hydroxylamine, which is converted into nitric oxide , 2004, British journal of pharmacology.

[94]  R. Lindberg,et al.  Cytosolic persistence of mouse brain CYP1A1 in chronic heme deficiency , 2005, Biological chemistry.

[95]  P. Böelle,et al.  Measurement of CYP2D6 and CYP3A4 activity in vivo with dextromethorphan: sources of variability and predictors of adverse effects in 419 healthy subjects , 2005, European Journal of Clinical Pharmacology.

[96]  E. Schuetz,et al.  Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. , 2005, Current drug metabolism.

[97]  V. Ravindranath,et al.  Constitutive expression and localization of cytochrome P‐450 1A1 in rat and human brain: presence of a splice variant form in human brain 1 , 2005, Journal of neurochemistry.

[98]  D. Lipscombe.  Neuronal proteins custom designed by alternative splicing , 2005, Current Opinion in Neurobiology.

[99]  Teruhiko Yoshida,et al.  FUNCTIONAL ANALYSIS OF SIX HUMAN ARYL HYDROCARBON RECEPTOR VARIANTS IN A JAPANESE POPULATION , 2005, Drug Metabolism and Disposition.

[100]  M. Tramèr,et al.  The effect of cigarette smoking on the hypnotic efficacy of propofol , 2006, Anaesthesia.

[101]  Anna M. Lee,et al.  CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment , 2006, Neuropharmacology.

[102]  V. Ravindranath,et al.  Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: the convolution continues , 2006, Expert opinion on drug metabolism & toxicology.

[103]  R. Tyndale,et al.  Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. , 2006, Journal of neural transmission. Supplementum.

[104]  A. Rifkind.  CYP1A in TCDD Toxicity and in Physiology–with Particular Reference to CYP Dependent Arachidonic Acid Metabolism and other Endogenous Substrates , 2006, Drug metabolism reviews.

[105]  R. Tyndale,et al.  Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine , 2006, Neuropharmacology.

[106]  V. Ravindranath,et al.  An alternatively spliced cytochrome P4501A1 in human brain fails to bioactivate polycyclic aromatic hydrocarbons to DNA‐reactive metabolites , 2007, Journal of neurochemistry.

[107]  D. Shields,et al.  An investigation of potential genetic determinants of propofol requirements and recovery from anaesthesia , 2007, European journal of anaesthesiology.

[108]  K. Otani,et al.  CYP2C19 polymorphism affects personality traits of Japanese females , 2007, Neuroscience Letters.

[109]  A. Llerena,et al.  CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. , 2007, Pharmacogenomics.

[110]  P. Gervasi,et al.  Expression, microsomal and mitochondrial activities of cytochrome P450 enzymes in brain regions from control and phenobarbital-treated rabbits. , 2007, Life sciences.

[111]  Anna M. Lee,et al.  CYP2B6 Genotype Alters Abstinence Rates in a Bupropion Smoking Cessation Trial , 2007, Biological Psychiatry.

[112]  R. Tyndale,et al.  Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats , 2008, Psychopharmacology.

[113]  K. Iwahashi,et al.  [Correlation analyses of ALDH2 and CYP2E1 genetic polymorphism with personality]. , 2008, Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence.

[114]  K. Goto,et al.  Association study of the cytochrome P450 17 gene polymorphism with personality traits in healthy subjects , 2008, Behavioural Brain Research.

[115]  Hongbing Wang,et al.  CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. , 2008, Current drug metabolism.

[116]  Marie-Anne Loriot,et al.  Xenobiotic metabolizing enzymes in the central nervous system: Contribution of cytochrome P450 enzymes in normal and pathological human brain. , 2008, Biochimie.

[117]  C. Daumas-Duport,et al.  ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood–brain barrier , 2008, Journal of neurochemistry.

[118]  Deborah C. Mash,et al.  Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment , 2008, Neuropharmacology.

[119]  M. Sikora,et al.  The Endocannabinoid Anandamide Is a Substrate for the Human Polymorphic Cytochrome P450 2D6 , 2008, Journal of Pharmacology and Experimental Therapeutics.

[120]  R. Tyndale,et al.  Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. , 2008, Journal of psychiatry & neuroscience : JPN.

[121]  R. Tyndale,et al.  Brain Drug-Metabolizing Cytochrome P450 Enzymes are Active In Vivo, Demonstrated by Mechanism-Based Enzyme Inhibition , 2009, Neuropsychopharmacology.

[122]  E. Kalkhoven,et al.  Functional implications of genetic variation in human PPARγ , 2009, Trends in Endocrinology & Metabolism.

[123]  S. Kawato,et al.  Retinoic acid stimulates 17beta-estradiol and testosterone synthesis in rat hippocampal slice cultures. , 2009, Endocrinology.

[124]  Bo Wang,et al.  New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme , 2009, Drug metabolism reviews.

[125]  M. Quik,et al.  Multiple roles for nicotine in Parkinson's disease. , 2009, Biochemical pharmacology.

[126]  Shufeng Zhou.  Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance , 2009, Clinical pharmacokinetics.

[127]  N. Benowitz,et al.  Nicotine chemistry, metabolism, kinetics and biomarkers. , 2009, Handbook of experimental pharmacology.

[128]  Wei Duan,et al.  Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. , 2009, Current drug metabolism.

[129]  Jian Cai,et al.  Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. , 2009, Current medicinal chemistry.

[130]  C. Hagemeyer,et al.  Concordant up‐regulation of cytochrome P450 Cyp3a11, testosterone oxidation and androgen receptor expression in mouse brain after xenobiotic treatment , 2009, Journal of neurochemistry.

[131]  M. Ingelman-Sundberg,et al.  Epigenetic and microRNA-dependent control of cytochrome P450 expression: a gap between DNA and protein. , 2009, Pharmacogenomics.

[132]  M. Loriot,et al.  Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function , 2009, Drug Metabolism and Disposition.

[133]  Shufeng Zhou,et al.  Polymorphism of human cytochrome P450 enzymes and its clinical impact , 2009, Drug metabolism reviews.

[134]  Effect of the cytochrome P450 19 (aromatase) gene polymorphism on personality traits in healthy subjects , 2009, Behavioural Brain Research.

[135]  R. Tyndale,et al.  Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. , 2010, Annual review of pharmacology and toxicology.

[136]  E. Bromek,et al.  The ability of cytochrome P450 2D isoforms to synthesize dopamine in the brain: An in vitro study. , 2010, European journal of pharmacology.

[137]  R. Tyndale,et al.  Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors , 2010, Brain Research.

[138]  Marie-Anne Loriot,et al.  ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders , 2010, Expert opinion on drug metabolism & toxicology.

[139]  Yonggong Zhai,et al.  Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism. , 2010, Advanced drug delivery reviews.

[140]  Z. Dvořák,et al.  Regulation of drug-metabolizing cytochrome P450 enzymes by glucocorticoids , 2010, Drug metabolism reviews.

[141]  R. Tyndale,et al.  Cytochrome P450 2D6 enzyme neuroprotects against 1‐methyl‐4‐phenylpyridinium toxicity in SH‐SY5Y neuronal cells , 2010, The European journal of neuroscience.

[142]  A. H. Tolson,et al.  Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. , 2010, Advanced drug delivery reviews.

[143]  Edoardo Spina,et al.  Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism , 2011, Expert opinion on drug metabolism & toxicology.

[144]  P. Sótonyi,et al.  Prodrugs and active metabolites among antidepressive compounds. , 2011, Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology.

[145]  Noam Shomron,et al.  MicroRNA pharmacogenomics: post-transcriptional regulation of drug response. , 2011, Trends in molecular medicine.

[146]  R. Shawahna,et al.  Interplay of drug metabolizing CYP450 enzymes and ABC transporters in the blood-brain barrier. , 2011, Current drug metabolism.

[147]  J Kirchheiner,et al.  CYP2D6 in the brain: genotype effects on resting brain perfusion , 2011, Molecular Psychiatry.

[148]  R. Tyndale,et al.  Drug Metabolism within the Brain Changes Drug Response: Selective Manipulation of Brain CYP2B Alters Propofol Effects , 2011, Neuropsychopharmacology.

[149]  D. Nelson,et al.  Progress in tracing the evolutionary paths of cytochrome P450. , 2011, Biochimica et biophysica acta.

[150]  E. Bromek,et al.  The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. , 2011, European journal of pharmacology.

[151]  E. Bromek,et al.  Cytochrome P450 mediates dopamine formation in the brain in vivo , 2011, Journal of neurochemistry.

[152]  Natasha T. Snider,et al.  Anandamide Oxidation by Wild-Type and Polymorphically Expressed CYP2B6 and CYP2D6 , 2011, Drug Metabolism and Disposition.

[153]  S. Preskorn,et al.  Antidepressant Treatment and Altered CYP2D6 Activity: Are Pharmacokinetic Variations Clinically Relevant? , 2011, Journal of psychiatric practice.

[154]  C. Klaassen,et al.  Epigenetic regulation of drug processing genes , 2011, Toxicology mechanisms and methods.

[155]  W. Schunck,et al.  Role of cytochrome P450 enzymes in the bioactivation of polyunsaturated fatty acids. , 2011, Biochimica et biophysica acta.

[156]  O. Zuiderveld,et al.  Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic , 2011, PAIN®.

[157]  R. Tyndale,et al.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.

[158]  Joseph McGraw,et al.  Cytochrome P450 variations in different ethnic populations , 2012, Expert opinion on drug metabolism & toxicology.

[159]  R. Tyndale,et al.  Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[160]  J. van Honk,et al.  Testosterone, cortisol, and serotonin as key regulators of social aggression: A review and theoretical perspective , 2011, Motivation and Emotion.

[161]  J. Olson,et al.  Biotransformation of Insecticides , 2012 .

[162]  D. Mash,et al.  The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients , 2012, Neurobiology of Aging.

[163]  J. Brockmöller,et al.  Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function , 2013, Molecular Psychiatry.